News

Euclid Vision Announces Acquisition of Visionary Optics

Euclid Vision Corp., a global leader in advanced orthokeratology and proactive myopia management initiatives, is pleased to announce its acquisition of Visionary Optics, a specialty scleral contact lens design and distribution pioneer. The acquisition signifies Euclid’s recognition of the value of joining forces with Visionary Optics, the only company in the US that concentrates almost exclusively on scleral contact lenses. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.

“We are excited about joining forces with Visionary Optics. This union opens exciting opportunities for cross-company collaboration and innovation,” said Joseph Boorady, Euclid President and CEO. “Visionary Optics, with its best-in-class scleral lens innovations and world class customer service, is a great match for the Euclid portfolio. Having market leading technologies in two of the fastest growing specialty contact lens markets — Ortho-K and scleral lenses — positions us to better serve our customers and their patients.”

Euclid and Visionary Optics share many of the same cultural values, such as a dedication to professional education, strong partnerships with eye care professionals, and market savvy product innovation. Each company will retain their unique individual brand, while being perfectly positioned to reap the benefits of shared future endeavors.

“This is an incredible opportunity for Visionary Optics to work with a partner who can help take our business and technology to the next level, while also maintaining the key foundational aspects of what has fueled our success including our customer-driven corporate culture and high-tech research orientation,” said Donald Sanders, MD, PhD Visionary Optics President and CEO.

Euclid and Visionary Optics understand that clinicians partner with companies that not only offer unparalleled lens design and the highest-level of advanced manufacturing, but those that also provide exceptional customer service. “Expert customer service is critical to the success of the clinicians who work with us, and we pride ourselves on the level of expertise for which our customer service team is known,” said Dr. Sanders. “As we unite with Euclid, preserving these team values are integral to maintaining our role as a leader in scleral lens design and distribution. Thus, our customers can count on the same great service they are used to with Visionary Optics.”

Recent News

02/05/2025

Project Vital bringing millions in funding to Roanoke-Blacksburg’s life sciences

The Roanoke-Blacksburg region is establishing itself as a biomedical research hub and medical device innovation center. About $5 million from the state could help move that work from labs to markets. Those millions will fund Project Vital: Virginia Innovations and Technology Advancements in Life Sciences. It’s a collaboration among the Roanoke-Blacksburg Innovation Alliance (formerly Verge),

01/31/2025

AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated

01/30/2025

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who